PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Immuno-Oncology (IO) is uniquely positioned to become the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy, and other targeted treatments. In order to assist our clients with navigating the burgeoning amount information arising as a result of the rapidly growing field of IO clinical research, GlobalData is offering a comprehensive analysis of both pipeline and marketed active immunity IO therapies

Scope

The PharmaFocus consists of a highly-visual slide deck that is intended to facilitate the dissemination of aggregated data and insights from analyses of over 800 IO products that are either marketed or in Phase I-III of clinical development.

Types of graphical analyses include:

Cumulative Plots

Aggregated Bubble Plots

Pie Charts

Matrix Analyses

Unique, actionable insights applicable to IO drugs in five major categories: Immune Checkpoint Modulators, Cellular Immunotherapies, Oncolytic Viruses, Peptide Vaccines, and Bispecific T-Cell Engagers are provided in this report.

Analysis of over 4000 clinical trials enrolling patients with 18 solid tumors and eight hematological cancers are included.

Key Highlights

Key Topics Covered

• Immune Checkpoint Modulators – Trends in Clinical Trial Development

• Competitive Assessment of Marketed PD-(L)1 Checkpoint Modulators

• Emergence of New Immune Checkpoint Targets

• Clinical and Commercial Opportunities for Highly Anticipated CAR Cell Therapies

• Cell Vaccines: Steady Development Stimulated by Prior IO Success

• Promising IO-IO Combinations Utilizing Oncolytic Viruses

Table of Contents

Table of Contents

1. Preface

1.1 Related Reports

1.2 Upcoming Reports

1.3 Abbreviations

2. Immuno-Oncology Product Definition and Classification

3. Recent Timeline of Immuno-Oncology Approvals

4. Immune Checkpoint Modulators – Trends in Clinical Trial Development

4.1 Clinical Trial Activity for Checkpoint Modulators Remains Essentially Driven by PD-(L)1 and CTLA-4 Targeting Agents

4.2 Academic Institutions Are Key Drivers for Early Stage Clinical Research, but Patient Recruitment is Highly Dependent on Companies

4.3 Geographic Locations of Trials Assessing Immune Checkpoint Modulators

5. Competitive Assessment of Marketed PD-(L)1 Checkpoint Modulators

5.1 Clinical Positioning of Marketed PD-(L)1 Inhibitors

5.2 Commercial Attributes of Marketed PD-(L)1 Checkpoint Modulators

5.3 Dynamic of Clinical Development for Marketed PD-(L)1 Checkpoint Modulators

5.4 Clinical Development Coverage of Marketed PD-(L)1 Checkpoint Modulators in Solid Tumors and Blood Cancers

6. Emergence of New Immune Checkpoint Targets

6.1 Emergence of New Checkpoint Targets in Clinical Development

6.2 Clinical Development Coverage of Emerging Targets in Solid Tumors and Blood Cancers – Matrix Analysis

7. Cellular Immunotherapies in Clinical Development

7.1 Clinical Development of Cellular Immunotherapies

7.2 Clinical Development of Cytotoxic Cellular Immunotherapies

8. Clinical and Commercial Opportunities for Highly Anticipated CAR Cell Therapies

8.1 Development of and Opportunities for CAR Cell Therapies

8.2 Development of CAR Cell Therapies in Blood Cancers

8.3 Development of CAR Cell Therapies in Solid Tumors

9. Cell Vaccines: Steady Development Stimulated by Prior IO Success

9.1 Trends in Clinical Development of Cancer Vaccines

10. T-cell Redirecting Therapies: Comparison Between CAR Cell Therapies and Bispecific T-Cell Engager Antibodies

10.1 Development of CAR Cell Therapies and Bispecific T-Cell Engagers

11. Promising IO-IO Combinations Utilizing Oncolytic Viruses

11.1 Combination Strategies of Oncolytic Viruses with Other IO Agents Create New Clinical Opportunities

12. Appendix

12.1 Inclusion Criteria for IO Products

12.2 Exclusion Criteria for IO Products

12.3 Identification of Immuno-Oncology Products Based on Targets and Molecule Types

12.4 Data Export from the Pharma Intelligence Center

12.5 Primary Research

12.6 Bibliography

12.7 About the Authors

12.8 About GlobalData

12.9 Contact Us

12.10 Disclaimer

Frequently asked questions

PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities thematic reports
Currency USD
$7,995

Can be used by individual purchaser only

$23,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities in real time.

  • Access a live PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.